Erenumab (AMG-334) (INN, trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines.
Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine .
Applications:Suitable for use in ELISA and SDS-PAGE.
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
抗体種類：Mab
宿主：human
Grade：Highly Purified
Purity：≥95%
Form：Supplied as a liquid in PBS, pH 7.5.
Specificity：Recognizes Erenumab (CALCRL/CGRP-R).
Isotype：IgG2,l
Calc Applications Abbrev：E
Immunogen：Recombinant protein corresponding to CALCRL/CGRP-R [Homo sapiens], expressed in CHO cells.
